This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (171)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Dementias  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Aging/ Geriatrics  • Alert me on articles by topic

Kenneth Rockwood, MD, FRCPC; Susan Kirkland, PhD; David B. Hogan, MD, FRCPC; Chris MacKnight, MD, MSc, FRCPC; Heather Merry, MSc; René Verreault, MD, PhD; Christina Wolfson, PhD; Ian McDowell, PhD

Arch Neurol. 2002;59:223-227.

Background  Recent reports suggest a possibly protective effect for statins in patients with Alzheimer disease. This association could be due to indication bias, ie, people who elect to take lipid-lowering agents (LLAs) may be healthier than those who do not, so that it may be these other health factors that explain their lower risk of dementia.

Objectives  To examine the association between the use of LLAs and dementia, adjusting for other markers of health, and to investigate factors associated with LLA use.

Design  A cohort study of LLA use and a case-control study of dementia in relation to LLA use, in a secondary analysis of the Canadian Study of Health and Aging.

Setting  A nationally representative population-based survey of Canadians 65 years and older.

Participants  To examine features associated with statin use, we evaluated data on 2305 people for whom health information, drug use, and cognitive status were known. To examine the relationship between LLA use and dementia, we selected incident cases of dementia (n = 492, of whom 326 had Alzheimer disease) that occurred between the first and second waves of the study. Control subjects were 823 persons examined during the first and second phases of the Canadian Study of Health and Aging who had no cognitive impairment.

Results  Use of LLAs was significantly (P<.001) more common in younger (65-79 years) than in older (80 years) people. It was not associated with other factors indicating a healthy lifestyle, but was associated with a history of smoking and hypertension. Use of statins and other LLAs reduced the risk of Alzheimer disease in subjects younger than 80 years, an effect that persisted after adjustment for sex, educational level, and self-rated health (odds ratio, 0.26; 95% confidence interval, 0.08-0.88). There was no significant effect in subjects 80 years and older.

Conclusions  While the possibility of indication bias in the original observations cannot be excluded, it was not demonstrated in LLA use in this study. Lipid-lowering agent use was associated with a lower risk of dementia, and specifically of Alzheimer disease, in those younger than 80 years. Further research is warranted.

From the Departments of Medicine (Drs Rockwood and MacKnight and Ms Merry) and Community Health and Epidemiology (Dr Kirkland), Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia; Department of Medicine, University of Calgary, Calgary, Alberta (Dr Hogan); Department of Social and Preventive Medicine, Université Laval, Sainte-Foy, Québec (Dr Verreault); Division of Geriatric Medicine, Department of Epidemiology and Biostatistics, McGill University, Montréal, Quebec (Dr Wolfson); and Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario (Dr McDowell).

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(2):321-322.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Statins, incident Alzheimer disease, change in cognitive function, and neuropathology
Arvanitakis et al.
Neurology 2008;70:1795-1802.
ABSTRACT | FULL TEXT  

Alzheimer's and Non-Alzheimer's Dementia: A Critical Review of Pharmacological and Nonpharmacological Strategies
Saddichha and Pandey
AM J ALZHEIMERS DIS OTHER DEMEN 2008;23:150-161.
ABSTRACT  

HMG-CoA Reductase Inhibitor Simvastatin Inhibits Cell Cycle Progression at the G1/S Checkpoint in Immortalized Lymphocytes from Alzheimer's Disease Patients Independently of Cholesterol-Lowering Effects
Sala et al.
J. Pharmacol. Exp. Ther. 2008;324:352-359.
ABSTRACT | FULL TEXT  

Association of statin use with cognitive decline in elderly African Americans
Szwast et al.
Neurology 2007;69:1873-1880.
ABSTRACT | FULL TEXT  

Statins prevent cholinesterase inhibitor blockade of sympathetic {alpha}7-nAChR-mediated currents in rat superior cervical ganglion neurons
Mozayan and Lee
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H1737-H1744.
ABSTRACT | FULL TEXT  

Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease
Li et al.
Neurology 2007;69:878-885.
ABSTRACT | FULL TEXT  

Simvastatin inhibits IFN-{gamma}-induced CD40 gene expression by suppressing STAT-1{alpha}
Lee et al.
J. Leukoc. Biol. 2007;82:436-447.
ABSTRACT | FULL TEXT  

High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels.
Thelen et al.
J Clin Pharmacol 2006;46:812-816.
ABSTRACT | FULL TEXT  

Brain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of Pravastatin
Thelen et al.
J. Pharmacol. Exp. Ther. 2006;316:1146-1152.
ABSTRACT | FULL TEXT  

Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline?
Alagiakrishnan et al.
Postgrad. Med. J. 2006;82:101-105.
ABSTRACT | FULL TEXT  

Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease
Masse et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:1624-1629.
ABSTRACT | FULL TEXT  

Mechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle et al.
J. Biol. Chem. 2005;280:34202-34209.
ABSTRACT | FULL TEXT  

Characteristics of selectors of nicotine replacement therapy
Shiffman et al.
Tobacco Control 2005;14:346-355.
ABSTRACT | FULL TEXT  

Statin Use and the Risk of Incident Dementia: The Cardiovascular Health Study
Rea et al.
Arch Neurol 2005;62:1047-1051.
ABSTRACT | FULL TEXT  

APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study
Dufouil et al.
Neurology 2005;64:1531-1538.
ABSTRACT | FULL TEXT  

Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
Lane and Farlow
J. Lipid Res. 2005;46:949-968.
ABSTRACT | FULL TEXT  

Association of active {gamma}-secretase complex with lipid rafts
Urano et al.
J. Lipid Res. 2005;46:904-912.
ABSTRACT | FULL TEXT  

Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease: Preliminary Results
Sparks et al.
Arch Neurol 2005;62:753-757.
ABSTRACT | FULL TEXT  

Do Statins Reduce Risk of Incident Dementia and Alzheimer Disease?: The Cache County Study
Zandi et al.
Arch Gen Psychiatry 2005;62:217-224.
ABSTRACT | FULL TEXT  

Chronic Administration of Statins Alters Multiple Gene Expression Patterns in Mouse Cerebral Cortex
Johnson-Anuna et al.
J. Pharmacol. Exp. Ther. 2005;312:786-793.
ABSTRACT | FULL TEXT  

Midlife cardiovascular risk factors and risk of dementia in late life
Whitmer et al.
Neurology 2005;64:277-281.
ABSTRACT | FULL TEXT  

3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate {beta}-Amyloid-Induced Microglial Inflammatory Responses
Cordle and Landreth
J. Neurosci. 2005;25:299-307.
ABSTRACT | FULL TEXT  

Mixed Dementia: Emerging Concepts and Therapeutic Implications
Langa et al.
JAMA 2004;292:2901-2908.
ABSTRACT | FULL TEXT  

Inhibition of Geranylgeranylation Mediates the Effects of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors on Microglia
Bi et al.
J. Biol. Chem. 2004;279:48238-48245.
ABSTRACT | FULL TEXT  

Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study
Li et al.
Neurology 2004;63:1624-1628.
ABSTRACT | FULL TEXT  

Brain Cholesterol: Long Secret Life Behind a Barrier
Bjorkhem and Meaney
Arterioscler. Thromb. Vasc. Bio. 2004;24:806-815.
ABSTRACT | FULL TEXT  

Caffeine as a Neuroprotective Adenosine Receptor Antagonist
Dall'Igna et al.
The Annals of Pharmacotherapy 2004;38:717-718.
FULL TEXT  

Plasma Levels of {beta}-Amyloid(1-40), {beta}-Amyloid(1-42), and Total {beta}-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins
Hoglund et al.
Arch Neurol 2004;61:333-337.
ABSTRACT | FULL TEXT  

The Role of Cholesterol and Statins in Alzheimer's Disease
Miller and Chacko
The Annals of Pharmacotherapy 2004;38:91-98.
ABSTRACT | FULL TEXT  

Serum lipids and memory in a population based cohort of middle age women
Henderson et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:1530-1535.
ABSTRACT | FULL TEXT  

Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease
Chauhan
J. Lipid Res. 2003;44:2019-2029.
ABSTRACT | FULL TEXT  

Reduction in Levels of 24S-Hydroxycholesterol by Statin Treatment in Patients With Alzheimer Disease
Vega et al.
Arch Neurol 2003;60:510-515.
ABSTRACT | FULL TEXT  

Diet and risk of dementia: Does fat matter?: The Rotterdam Study
Engelhart et al.
Neurology 2002;59:1915-1921.
ABSTRACT | FULL TEXT  

Induction of the Cholesterol Transporter ABCA1 in Central Nervous System Cells by Liver X Receptor Agonists Increases Secreted Abeta Levels
Fukumoto et al.
J. Biol. Chem. 2002;277:48508-48513.
ABSTRACT | FULL TEXT  

A Cross-Sectional Study of Lipids and ApoC Levels in Alzheimer's Patients With and Without Cardiovascular Disease
Adunsky et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2002;57:M757-761.
ABSTRACT | FULL TEXT  

Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study
Zandi et al.
Neurology 2002;59:880-886.
ABSTRACT | FULL TEXT